January 31, 2026 Sacituzumab Govitecan + Pembrolizumab Prolongs Progression-Free Survival in Triple-Negative Breast Cancer
January 31, 2026 State Recommendations for Routine Childhood Vaccines: Increasing Departure from Federal Guidelines
